What changed from existing technology?
This study shows that making a part of a protein called ErbB2 in breast cancer cells makes the nucleus softer and helps the cells move more, which could help cancer spread.
This study is the first to demonstrate that controlled expression of a single oncogene, p95HER2, can directly alter nuclear mechanics and cell migration without requiring additional genetic changes.
Commercialization signals visible at publication
This is not a success probability or investment opinion. It prioritizes follow-up using evidence available when the paper was published.
Verified evidence · 1
g cancer cell lines with varying metastatic potential remain poorly understood, despite their clear therapeutic relevance. While comparisons between mali
Abstract ↗- 시제품·장치 구현 근거 미확인
- 제조·규모 확장 근거 미확인
- 장기·실사용 검증 근거 미확인
Later patent, company, clinical, and production events are added separately only after verification.
Patent check: Not checked yetCurrent technology stage: Early research
See what changed before reading the full paper.
What still needs to be solved?
Repeated real-world validation, manufacturability, cost, and long-term stability still require follow-up evidence.
What could change if this succeeds?
This finding could help in understanding how specific genetic changes contribute to cancer progression and may inform the development of therapies targeting nuclear mechanics in cancer cells.
Keep following this technology
Revisit changes when new papers, patents, company participation, validation, or products appear.